DURECT’s psoriasis treatment, DUR-928, did not demonstrate a significant benefit over a placebo in trials, though it was well tolerated in the 22 patients tested. Based on these results, the company will stop development on DUR-928 and will instead focus on their alcoholic hepatitis treatment, which achieved positive results in its phase 2a trial. While not all clinical trials are successful, Yourway provides solutions and services to move a therapy all the way through to commercialization.